Takeda drops 'me-too' Zytiga after disappointing Phase III
This article was originally published in Scrip
Takeda has terminated the Phase III development of orteronel (TAK-700) for prostate cancer. The decision is not a surprise as it follows the failure of two Phase III trials in metastatic, castration-resistant prostate cancer (mCRPC). The studies found while orteronel plus prednisone could extend progression free survival (PFS), it did not extend overall survival (OS) in these patients.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.